Us Ventral Hernia Mesh Devices Market Report CAGR 8.27%

The US ventral hernia mesh devices market is projected to grow from $382.8 million in 2025 to $762.5 million by 2033, expanding at a CAGR of 8.27%. This growth is driven by rising hernia incidence, aging population, and adoption of robotic surgery. The Surgical Mesh Market in the US is also benefiting from technological advancements in mesh materials. Non-resorbable meshes, particularly polypropylene, dominate with over 65% revenue share in 2025. However, resorbable and partially absorbable meshes are gaining traction due to lower infection rates. The Inpatient Facilities Market remains the primary end-user, accounting for 70% of procedures, though outpatient settings are growing faster. Key players are focusing on product innovation and strategic partnerships to capture share. The market faces restraints from regulatory hurdles and reimbursement uncertainties. The Robotic Surgery Market is expanding rapidly, creating demand for robot-compatible meshes. Overall, the outlook remains positive, with robotic surgery and biologic meshes as key growth frontiers.

The Non-resorbable Mesh Market is the largest, generating $248.8 million in 2025. The Polypropylene Mesh Market dominates the non-resorbable segment, accounting for over 80% of revenue. However, the Resorbable Mesh Market is the fastest-growing, driven by clinical evidence showing reduced complications. The Incisional Hernia Market represents over 40% of all ventral hernia repairs, with mesh reinforcement standard in open and laparoscopic procedures. The Laparoscopic Surgery Market is expanding as minimally invasive techniques reduce recovery times. Margin pressures are intensifying as hospitals consolidate purchasing and demand price transparency. Manufacturers are responding by developing composite meshes and offering value-based contracts. The Outpatient Facilities Market is gaining share for simpler hernia repairs, while complex cases remain inpatient.

The US market is propelled by demographic and technological factors. The aging population is a primary driver, with over 70 million Americans expected to be over 65 by 2030, significantly increasing hernia prevalence. Robotic surgery adoption, growing at 15% annually, enhances surgical precision and drives demand for specialized meshes. However, regulatory scrutiny following past mesh recalls has led to stricter FDA requirements, raising compliance costs by an estimated 20%. Reimbursement pressures from Medicare and private insurers also restrain pricing. Supply chain issues, particularly for polypropylene, remain a concern. Despite these challenges, innovation in resorbable and biologic meshes presents opportunities.

• Medtronic plc: Leverages its Hugo RAS system to offer integrated mesh solutions, targeting complex ventral hernia repairs. The company holds an estimated 22% US market share.
• Ethicon Inc. (Johnson & Johnson MedTech): Dominates with Prolene and Physiomesh brands, focusing on clinical evidence and surgeon training programs. Its 30% share makes it the market leader.
• Becton, Dickinson and Company: Offers a range of mesh fixation devices and synthetic meshes, with a growing presence in laparoscopic procedures.
• W. L. Gore & Associates, Inc.: Known for GORE BIO-A and SYNECOR meshes, catering to challenging cases requiring biocompatibility.
• TELA Bio, Inc.: Specializes in ovine-based resorbable meshes, targeting patients at risk of infection. Recent launch of OviTex PRS gained traction.
• B. Braun SE: Provides cost-effective mesh solutions, particularly in outpatient settings, with a focus on emerging technologies.

• 2021: W. L. Gore acquired a biologic mesh startup, enhancing its resorbable product line.
• 2022: Ethicon partnered with Intuitive Surgical to develop meshes optimized for da Vinci systems, improving surgical outcomes.
• 2023: Medtronic acquired a robotic surgery startup, aiming to combine its mesh technology with the Hugo RAS platform. B. Braun received FDA clearance for its C-QUR Edge mesh, expanding its US presence.
• 2024: TELA Bio launched OviTex PRS, a resorbable mesh for ventral hernia, capturing attention in the high-risk patient segment.

• North America (US) is the most mature market, with $382.8 million in 2025, driven by high procedure rates and technological adoption. The US accounts for over 80% of North American revenue.
• Asia-Pacific is the fastest-growing region, projected at 10.2% CAGR, fueled by expanding healthcare access in China and India, and rising adoption of laparoscopic surgery.
• Europe remains a strong market, with stringent regulations ensuring safety but slowing product approvals. The Resorbable Mesh Market is gaining traction here.
• LAMEA offers untapped potential, but limited reimbursement and infrastructure pose challenges. The Outpatient Facilities Market is emerging in urban centers.

The end-user base is segmented into inpatient and outpatient facilities. Inpatient Facilities Market dominates, accounting for 70% of mesh procedures in 2024, driven by complex hernia repairs requiring overnight stays. Outpatient Facilities Market is growing at 9.5% CAGR as simpler repairs shift to ambulatory surgery centers. Decision-making criteria include clinical evidence, cost, and surgeon preference. Price elasticity is moderate; hospitals are consolidating purchases to negotiate discounts. Procurement channels are primarily direct sales and group purchasing organizations (GPOs). Digital purchasing habits are increasing, with online platforms for ordering and inventory management. Shifts in buyer expectations include demand for value-based contracts and real-time data on outcomes. The COVID-19 pandemic accelerated telehealth and remote proctoring, influencing purchasing decisions.

The US FDA regulates hernia meshes as Class II devices, requiring 510(k) clearance. Recent guidance emphasizes post-market surveillance and patient registries. The EU Medical Device Regulation (MDR) imposes stricter clinical evaluation requirements, impacting US manufacturers exporting to Europe. In Asia, Japan's PMDA and China's NMPA have unique approval pathways. ISO 13485 certification is mandatory for quality management. REACH regulations affect material sourcing, especially for polypropylene. Recent policy changes include the FDA's 2023 update on mesh safety communications, requiring enhanced labeling. Compliance costs are estimated at $500,000 to $2 million per product. These regulations drive consolidation, as smaller firms struggle to meet requirements. The market is also seeing increased scrutiny on informed consent and surgeon training.

• 1. Mesh Type
  • 1.1. Resorbable Mesh
  • 1.2. Partially Absorbable Mesh
  • 1.3. Non-resorbable Mesh
• 2. Indication
  • 2.1. Umbilical Hernia
  • 2.2. Epigastric Hernia
  • 2.3. Incisional Hernia
  • 2.4. Others
• 3. Procedure
  • 3.1. Open Surgery
  • 3.2. Laparoscopic Surgery
  • 3.3. Robotic Surgery
  • 3.4. Others
• 4. End Use
  • 4.1. Inpatient Facilities
  • 4.2. Outpatient Facilities

• 1. Us